Tag: business
-

J&J’s Rybrevant Faspro Gains FDA Accelerated Approval for Head and Neck Cancer
Rybrevant Faspro expands beyond lung cancer with FDA accelerated approval for certain adults with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Here’s who qualifies and what the OrigAMI-4 study showed.
-

Astellas Secures Option on Audax’s IL-12 Cancer Therapy DAX-044
Astellas secured an option to license Audax’s DAX-044, a preclinical IL-12 immunotherapy designed to focus immune activation within the tumor microenvironment.
-

GSK’s Hibsago Wins FDA Approval for Chronic Hepatitis B
GSK’s Hibsago (bepirovirsen) won FDA approval for selected adults with chronic hepatitis B. Explore its 19% functional cure result, RNA-targeting mechanism, treatment requirements and key safety risks.
-

Viatris and Opus’ Ryzumvi Wins FDA Approval for Adult Presbyopia
Ryzumvi wins FDA approval for adult presbyopia. Explore its pupil-reducing mechanism, Phase 3 results and the commercial challenges facing Viatris and Opus Genetics.
-

Roche’s Enspryng Wins FDA Approval for Thyroid Eye Disease
Roche’s Enspryng wins FDA approval for adult thyroid eye disease. Explore its IL-6 receptor blockade, antibody recycling technology, mixed Phase 3 results and the commercial implications of at-home treatment.
-

Viatris to Acquire Pacira for $1.65B in Non-Opioid Pain Push
Viatris agreed to acquire Pacira BioSciences for $1.65 billion, adding Exparel, Zilretta and an established U.S. specialty platform. The deal advances Viatris’ shift toward innovative medicines but also introduces patent, generic competition and integration risks.
-

Eli Lilly’s Jaypirca Wins FDA Approval for First-Line CLL/SLL
The noncovalent BTK inhibitor reduced the risk of progression or death by 80% versus bendamustine plus rituximab in previously untreated patients without known del(17p). Key Takeaways Data Snapshot Item Details Company Eli Lilly Drug Jaypirca (pirtobrutinib) FDA approval date October 2, 2026 Indication Previously untreated adult CLL/SLL without known del(17p) Pivotal trial Phase 3 BRUIN…
-

Novartis Licenses Abogen’s ABO2203 in $7.8B mRNA Deal
Novartis will pay Abogen $575 million upfront for worldwide rights to ABO2203, an mRNA-encoded CD19×CD3 T-cell engager, while securing options on additional RNA programs in a deal potentially worth approximately $7.8 billion.

